Latest "irbesartan amlodipine irbesartan Hypertension" News Stories

06:54 EST 24th November 2014 | BioPortfolio

Here are the most relevant search results for "irbesartan amlodipine irbesartan Hypertension" found in our extensive news archives from over 250 global news sources.

More Information about irbesartan amlodipine irbesartan Hypertension on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about irbesartan amlodipine irbesartan Hypertension for you to read. Along with our medical data and news we also list irbesartan amlodipine irbesartan Hypertension Clinical Trials, which are updated daily. BioPortfolio also has a large database of irbesartan amlodipine irbesartan Hypertension Companies for you to search.

Showing "irbesartan amlodipine irbesartan Hypertension" News Articles 1–25 of 946

Extremely Relevant

Human medicines European public assessment report (EPAR): Irbesartan Zentiva (previously Irbesartan Winthrop), irbesartan, Revision: 15, Authorised

Human medicines European public assessment report (EPAR): Irbesartan Hydrochlorothiazide Zentiva (previously Irbesartan Hydrochlorothiazide Winthrop), irbesartan / hydrochlorothiazide, Revision: 19, Authorised

Human medicines European public assessment report (EPAR): Irbesartan Teva, irbesartan, Revision: 5, Authorised

Human medicines European public assessment report (EPAR): Irbesartan Teva, irbesartan, Revision: 6, Authorised

Human medicines European public assessment report (EPAR): Ifirmasta (previously Irbesartan Krka), irbesartan, Revision: 5, Authorised

Human medicines European public assessment report (EPAR): Irbesartan/Hydrochlorothiazide Teva, irbesartan / hydrochlorothiazide, Revision: 7, Authorised

Human medicines European public assessment report (EPAR): Sabervel, irbesartan, Revision: 2, Authorised

Human medicines European public assessment report (EPAR): Aprovel, irbesartan, Revision: 32, Authorised

Human medicines European public assessment report (EPAR): Karvea, irbesartan, Revision: 31, Authorised

Human medicines European public assessment report (EPAR): Ifirmacombi, irbesartan / hydrochlorothiazide, Revision: 2, Authorised

Human medicines European public assessment report (EPAR): CoAprovel, irbesartan / hydrochlorothiazide, Revision: 30, Authorised

Human medicines European public assessment report (EPAR): Karvezide, irbesartan / hydrochlorothiazide, Revision: 31, Authorised

Relevant

Par Pharmaceutical Begins Shipment of Generic Exforge®

WOODCLIFF LAKE, N.J., Sept. 30, 2014 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that it has begun shipping all four strengths of amlodipine and valsartan tablets, the generic version of Novartis' Exforge®.  Par received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for amlodipine and valsartan and was grant...

Simultaneous Determination of Amlodipine and Its Counterion Besylate

Thermo Fisher Scientific has developed a simple, rapid, reliable, and accurate high-performance liquid chromatography (HPLC) method for the simultaneous determination of amlodipine and besylate in an amlodipine besylate drug substance. Application Note 1087: Simultaneous Determination of Amlodipine and Its Counterion Besylate by HPLC demonstrates that this method requires only ...

Efficacy of olmesartan/amlodipine combination therapy in reducing ambulatory blood pressure in moderate-to-severe hypertensive patients not controlled by amlodipine alone

Zacras® Combination Tablets LD and Zacras® Combination Tablets HD, Fixed-Dose Combination of Azilsartan and Amlodipine, and Azilva® Tablets 10mg, Treatment for Hypertension, are Now Available in Japan

News Release

Transfer of Distribution and Termination of Co-promotion for Caduet® Combination Tablets

Pfizer Japan Inc. (Tokyo, “Pfizer”) and Astellas Pharma Inc. (Tokyo: 4503, “Astellas”) today announced that the companies have agreed to terminate the distribution and co-promotion agreement in Japan for a combination drug o...

Interventional Management in Hypertension

What types of device-based interventions to lower drug-resistant hypertension have been developed over the last number of years, and how effective are they? Current Opinion in Nephrology and Hypertension

Which New Hypertension Guidelines Are the Best?

Three separate hypertension guidelines were released last year. Speakers at HYPERTENSION 2014 were tasked with convincing the audience which set of recommendations is the best. Heartwire

Resistant Hypertension or Noncompliance? A Push for Answers

Hypertension doctors gathering here are turning with renewed attention to the questions: how many patients truly have "resistant" hypertension, and what's the best way to get blood pressure down? Heartwire

Hypertension: Fluid overload and post-dialysis hypertension

Although intradialytic hypertension is associated with all-cause mortality, the mechanisms that underlie this phenomenon are not well understood. Now, Nongnuch et al. report that post-dialysis hypertension is associated with extracellular fluid over...

Hypertension, Lengthy Beta-Blocker Use May Provoke Psoriasis

In a prospective cohort study of women in their 60s, long-term use of beta-blockers for hypertension, and hypertension itself, were linked with a higher risk of developing psoriasis. Heartwire

Undiagnosed hypertension more likely in rheumatoid arthritis

(HealthDay)—Among patients meeting guideline-based criteria for hypertension, those with rheumatoid arthritis (RA) are less likely to receive a diagnosis of hypertension, according to a study published in the September issue of Arthritis Care & Res...

FDA Accepts New Drug Application for Symplmed’s Prestalia® for the Treatment of Hypertension

- First fixed-dose combination of ACE inhibitor, perindopril arginine, and calcium channel blocker, amlodipine besylate, to be reviewed in the U.S. - - Symplmed to Streamline Prescription Delivery Process through Proprietary DyrctAxess™ - Symplmed announced today that the U.S. Food and Drug Administration (FDA) has accepted for review...

Hypertension Partnering 2009-2014

Recently added to the BioPortfolio report store, Hypertension Partnering 2009-2014 is a new report from Current Partnering published on 2014-10-31. This 100+-page report is available from $995. The Hypertension Partnering 2009-2014 report provides understanding and access to the hypertension partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in hypert...


Search BioPortfolio:
Loading
Advertisement
Advertisement

News Quicklinks